Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1984 3
1985 3
1986 8
1987 8
1988 4
1989 5
1990 5
1991 7
1992 7
1993 6
1994 5
1995 9
1996 5
1997 8
1998 8
1999 8
2000 8
2001 3
2002 6
2003 8
2004 4
2005 13
2006 3
2007 6
2008 3
2009 9
2010 11
2011 5
2012 3
2013 4
2014 6
2015 2
2016 5
2017 9
2018 16
2019 13
2020 13
2021 6
2022 6
2023 4
2024 5

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

249 results

Results by year

Filters applied: . Clear all
Page 1
Prospective evaluation of prognostic impact of KIT mutations on acute myeloid leukemia with RUNX1-RUNX1T1 and CBFB-MYH11.
Ishikawa Y, Kawashima N, Atsuta Y, Sugiura I, Sawa M, Dobashi N, Yokoyama H, Doki N, Tomita A, Kiguchi T, Koh S, Kanamori H, Iriyama N, Kohno A, Moriuchi Y, Asada N, Hirano D, Togitani K, Sakura T, Hagihara M, Tomikawa T, Yokoyama Y, Asou N, Ohtake S, Matsumura I, Miyazaki Y, Naoe T, Kiyoi H. Ishikawa Y, et al. Among authors: asou n. Blood Adv. 2020 Jan 14;4(1):66-75. doi: 10.1182/bloodadvances.2019000709. Blood Adv. 2020. PMID: 31899799 Free PMC article.
A phase 1/2 study of NS-87/CPX-351 (cytarabine and daunorubicin liposome) in Japanese patients with high-risk acute myeloid leukemia.
Usuki K, Miyamoto T, Yamauchi T, Ando K, Ogawa Y, Onozawa M, Yamauchi T, Kiyoi H, Yokota A, Ikezoe T, Katsuoka Y, Takada S, Aotsuka N, Morita Y, Ishikawa T, Asada N, Ota S, Dohi A, Morimoto K, Imai S, Kishimoto U, Akashi K, Miyazaki Y; Study Group for NS-87/CPX-351. Usuki K, et al. Int J Hematol. 2024 Jun;119(6):647-659. doi: 10.1007/s12185-024-03733-z. Epub 2024 Mar 26. Int J Hematol. 2024. PMID: 38532078 Free PMC article. Clinical Trial.
Randomized study of induction therapy comparing standard-dose idarubicin with high-dose daunorubicin in adult patients with previously untreated acute myeloid leukemia: the JALSG AML201 Study.
Ohtake S, Miyawaki S, Fujita H, Kiyoi H, Shinagawa K, Usui N, Okumura H, Miyamura K, Nakaseko C, Miyazaki Y, Fujieda A, Nagai T, Yamane T, Taniwaki M, Takahashi M, Yagasaki F, Kimura Y, Asou N, Sakamaki H, Handa H, Honda S, Ohnishi K, Naoe T, Ohno R. Ohtake S, et al. Among authors: asou n. Blood. 2011 Feb 24;117(8):2358-65. doi: 10.1182/blood-2010-03-273243. Epub 2010 Aug 6. Blood. 2011. PMID: 20693429 Free article. Clinical Trial.
Cytokeratin expression in therapy-related leukemia.
Kinoshita H, Okamura D, Sato T, Taji Y, Kayano H, Yasuda M, Asou N, Ebihara Y. Kinoshita H, et al. Among authors: asou n. Int J Hematol. 2021 Feb;113(2):161-162. doi: 10.1007/s12185-020-03062-x. Epub 2021 Jan 1. Int J Hematol. 2021. PMID: 33385292 No abstract available.
Rosette-like formation in multiple myeloma.
Aoki M, Takahashi N, Taji Y, Yasuda M, Asou N, Ebihara Y. Aoki M, et al. Among authors: asou n. Ann Hematol. 2021 May;100(5):1357-1358. doi: 10.1007/s00277-020-04064-9. Epub 2020 May 7. Ann Hematol. 2021. PMID: 32382771 No abstract available.
[II.Acute Myeloid Leukemia].
Asou N. Asou N. Gan To Kagaku Ryoho. 2017 May;44(5):386-391. Gan To Kagaku Ryoho. 2017. PMID: 28536333 Japanese. No abstract available.
[Aleukemic leukemia].
Asou N. Asou N. Ryoikibetsu Shokogun Shirizu. 1998;(22 Pt 3):135-8. Ryoikibetsu Shokogun Shirizu. 1998. PMID: 9851103 Review. Japanese. No abstract available.
Real-world data of MDS and CMML in Japan: results of JALSG clinical observational study-11 (JALSG-CS-11).
Usuki K, Ohtake S, Honda S, Matsuda M, Wakita A, Nawa Y, Takase K, Maeda A, Sezaki N, Yokoyama H, Takada S, Hirano D, Tomikawa T, Sumi M, Yano S, Handa H, Ota S, Fujita H, Fujimaki K, Mugitani A, Kojima K, Kajiguchi T, Fujimoto K, Asou N, Usui N, Ishikawa Y, Katsumi A, Matsumura I, Miyazaki Y, Kiyoi H. Usuki K, et al. Among authors: asou n. Int J Hematol. 2024 Feb;119(2):130-145. doi: 10.1007/s12185-023-03686-9. Epub 2023 Dec 13. Int J Hematol. 2024. PMID: 38091231
Nilotinib vs dasatinib in achieving MR4.5 for de novo chronic myeloid leukemia: the randomized JALSG CML212 study.
Matsumura I, Ohtake S, Atsuta Y, Kurata M, Minami Y, Takahashi N, Nakaseko C, Iriyama N, Fujimaki K, Kakihana K, Ogasawara Y, Ono T, Okada M, Tauchi T, Miyamoto T, Ohnishi K, Sakaida E, Fujisawa S, Kobayashi Y, Asou N, Naoe T, Kiyoi H, Miyazaki Y. Matsumura I, et al. Among authors: asou n. Blood Adv. 2024 Oct 22;8(20):5237-5247. doi: 10.1182/bloodadvances.2024012655. Blood Adv. 2024. PMID: 38968156 Free PMC article. Clinical Trial.
249 results